Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts

Shares of Novavax, Inc. (NASDAQ:NVAX - Get Free Report) have received a consensus rating of "Hold" from the seven research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $17.00.

Several analysts have issued reports on NVAX shares. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock. B. Riley reaffirmed a "buy" rating on shares of Novavax in a report on Monday, May 19th. Citigroup assumed coverage on Novavax in a research note on Tuesday. They set a "sell" rating and a $6.00 price objective for the company. TD Cowen upgraded Novavax to a "hold" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. cut their price objective on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a report on Friday, May 9th.

Institutional Trading of Novavax

A number of hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in shares of Novavax during the fourth quarter worth approximately $27,000. New Age Alpha Advisors LLC purchased a new position in Novavax in the 4th quarter worth $35,000. AlphaQuest LLC raised its position in Novavax by 290.1% in the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 7,940 shares during the period. Kitching Partners LLC bought a new stake in Novavax in the fourth quarter worth $89,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Novavax during the first quarter valued at about $71,000. Institutional investors own 53.04% of the company's stock.

Novavax Stock Up 2.8%

Shares of NASDAQ:NVAX traded up $0.18 during midday trading on Tuesday, reaching $6.48. 3,055,968 shares of the company traded hands, compared to its average volume of 6,470,285. The firm's fifty day moving average price is $6.73 and its two-hundred day moving average price is $7.65. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 2.43, a price-to-earnings-growth ratio of 0.07 and a beta of 2.80. Novavax has a 12 month low of $5.01 and a 12 month high of $17.81.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, beating analysts' consensus estimates of $0.71 by $2.22. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The business had revenue of $666.66 million during the quarter, compared to analyst estimates of $204.08 million. During the same quarter in the previous year, the firm earned ($1.05) EPS. The company's quarterly revenue was up 610.3% compared to the same quarter last year. Analysts forecast that Novavax will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.